These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12401677)

  • 1. The impact of genomic and proteomic technologies on the development of new cancer drugs.
    Workman P
    Ann Oncol; 2002; 13 Suppl 4():115-24. PubMed ID: 12401677
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug discovery strategies: technologies to accelerate translation from target to drug.
    Workman P
    J Chemother; 2004 Nov; 16 Suppl 4():13-5. PubMed ID: 15688601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic future beckons for cancer management.
    Qadir Z
    Lancet; 2011 Nov; 378(9806):1838. PubMed ID: 22125803
    [No Abstract]   [Full Text] [Related]  

  • 4. Genomic medicines for oncology: early lessons.
    Simons JW
    J Med Assoc Ga; 2003; 92(1):35-8. PubMed ID: 12743904
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy.
    Robert J
    J Chemother; 2004 Nov; 16 Suppl 4():22-4. PubMed ID: 15688604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular therapeutics: promise and challenges.
    Kohn EC; Lu Y; Wang H; Yu Q; Yu S; Hall H; Smith DL; Meric-Bernstam F; Hortobagyi GN; Mills GB
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):39-53. PubMed ID: 15052542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preparing for genomic medicine].
    Mäkelä T
    Duodecim; 2004; 120(20):2399-404. PubMed ID: 15641508
    [No Abstract]   [Full Text] [Related]  

  • 8. Integration of genomic technologies for accelerated cancer drug development.
    Basik M; Mousses S; Trent J
    Biotechniques; 2003 Sep; 35(3):580-2, 584, 586 passim. PubMed ID: 14513563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in molecular targets and cancer therapeutics.
    Westwell AD
    Drug Discov Today; 2004 Mar; 9(5):207-9. PubMed ID: 14980538
    [No Abstract]   [Full Text] [Related]  

  • 10. Applications of proteomics in oncology.
    Jain KK
    Pharmacogenomics; 2000 Nov; 1(4):385-93. PubMed ID: 11257924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The erosion of research integrity: the need for culture change.
    Ellis LM
    Lancet Oncol; 2015 Jul; 16(7):752-4. PubMed ID: 26149871
    [No Abstract]   [Full Text] [Related]  

  • 12. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
    Nelson B
    Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
    [No Abstract]   [Full Text] [Related]  

  • 13. Sequence-based cancer genomics: progress, lessons and opportunities.
    Strausberg RL; Simpson AJ; Wooster R
    Nat Rev Genet; 2003 Jun; 4(6):409-18. PubMed ID: 12776211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis: emerging opportunities for therapeutic intervention.
    Evans CF; Shriver LP
    Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):17-30. PubMed ID: 12769632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An agenda for clinical trials: clinical trials in the genomic era.
    Simon RM
    Clin Trials; 2004; 1(5):468-70. PubMed ID: 16279285
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent advances in the pharmacogenetics of cancer chemotherapy.
    Watters JW; McLeod HL
    Curr Opin Mol Ther; 2002 Dec; 4(6):565-71. PubMed ID: 12596358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression microarray technologies in the development of new therapeutic agents.
    Clarke PA; te Poele R; Workman P
    Eur J Cancer; 2004 Nov; 40(17):2560-91. PubMed ID: 15541959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individuated molecular target chemotherapy].
    Yamamoto W; Endo W; Sato A; Matsukawa M
    Nihon Rinsho; 2002 Jan; 60(1):168-73. PubMed ID: 11808329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversy and debate on clinical genomics sequencing-paper 1: genomics is not exceptional: rigorous evaluations are necessary for clinical applications of genomic sequencing.
    Wilson BJ; Miller FA; Rousseau F
    J Clin Epidemiol; 2017 Dec; 92():4-6. PubMed ID: 28870871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
    Lin F; Li Z; Hua Y; Lim YP
    Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.